The anti-CTLA4-TGFβ-R2 molecule is more effective than ipilimumab (an anti-CTLA-4 antibody), at inhibiting tumor progression and decreasing tumor-infiltrating Treg cells (Ravi et al., 2018). Here, TGFBR2 is linked to neoplasm.